natgillin/translations-raw huggingface dataset:
Rifabutin 150 mg to gange ugentligt (atazanavir 300 mg 1 gang dagligt med ritonavir 100 mg 1 gang dagligt) 
Rifabutin 150 mg twice weekly (atazanavir 300 mg once daily with ritonavir 100 mg once daily)
Efavirenz 600 mg 1 gang dagligt (atazanavir 400 mg 1 gang dagligt) 
Efavirenz 600 mg once daily (atazanavir 400 mg once daily)
Interaktionsmekanismen er atazanavirs CYP3A4- og UGT1A1hæmning. 
The mechanism of interaction is CYP3A4 and UGT1A1 inhibition by atazanavir.
Omeprazol 40 mg 1 gang dagligt (atazanavir 300 mg 1 gang dagligt med ritonavir 100 mg 1 gang dagligt, 2 timer efter omeprazol) 
Omeprazole 40 mg once daily (atazanavir 300 mg once daily with ritonavir 100 mg once daily, 2 hours after omeprazole)
Klinisk monitorering anbefales hvis drospirenon/ethinylestradiol administreres samtidig med atazanavir/cobicistat, grundet potentiel hyperkaliæmi. 
If drospirenone/ethinyloestradiol is co-administered with atazanavir/cobicistat clinical monitoring is recommended due to the potential for hyperkalemia.
Interaktionsmekanismen er atazanavirs og cobicistats CYP3Aog/eller P-glycoprotein-hæmning. 
The mechanism of interaction is CYP3A and/or P-glycoprotein inhibition by atazanavir and cobicistat.
triazolam og oralt (indtaget gennem munden) midazolam (bruges som sovemedicin og/eller til at behandle angst) simvastatin og lovastatin (bruges til at sænke mængden af kolesterol i blodet) avanil (bruges til at behandle erektil dysfunktion (impotens)). 
triazolam and oral (taken by mouth) midazolam (used to help you sleep and/or to relieve anxiety) simvastatin and lovastatin (used to lower blood cholesterol) avanafil (used to treat erectile dysfunction) colchicine (used to treat gout), if you have kidney and/or liver problems ticagrelor (used to reduce the blood clots) grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination, and glecaprevir/pibrentasvir fixed dose combination (used to treat chronic hepatitis C infection)
Interaktionsmekanismen er CYP3A-hæmning. 
The mechanism of interaction is CYP3A inhibition.
Interaktionsmekanismen er rifampicins CYP3A4-induktion. 
The mechanism of interaction is CYP3A4 induction by rifampicin.
Omeprazol 20 mg 1 gang dagligt om morgenen (atazanavir 300 mg 1 gang dagligt med ritonavir 100 mg 1 gang dagligt om aftenen, 12 timer efter omeprazol) 
Omeprazole 20 mg once daily am (atazanavir 300 mg once daily with ritonavir 100 mg once daily pm, 12 hours after omeprazole)
Samtidig administration af følgende lægemidler, som er kraftige induktorer af CYP3A4-isoformen af cytochrom-P450 på grund af den potentielle risiko for tab af terapeutisk virkning (se pkt. 
Co-administration with the following medicinal products that are strong inducers of the CYP3A4 isoform of cytochrome P450 due to the potential for loss of therapeutic effect (see section 4.5): carbamazepine, phenobarbital, phenytoin (antiepileptics) St John's wort (Hypericum perforatum) (herbal product) rifampicin (antimycobacterial)
Interaktionsmekanismen er cobicistats CYP3A4- og P-gp-hæmning. 
The mechanism of interaction is CYP3A4 and P-gp inhibition by cobicistat.
Elbasvir 50 mg 1 gang dagligt (atazanavir 300 mg/ritonavir 100 mg 1 gang dagligt) 
Elbasvir 50 mg once daily (atazanavir 300 mg / ritonavir 100 mg once daily
Boceprevir 800 mg tre gange dagligt (atazanavir 300 mg/ritonavir 100 mg 1 gang dagligt) 
Boceprevir 800 mg three times daily (atazanavir 300 mg/ritonavir 100 mg once daily)
Plasmakoncentrationerne af atorvastatin øges ved samtidig administration med atazanavir/cobicistat 
Plasma concentrations of atorvastatin are increased when coadministered with atazanavir/cobicistat
Plasmakoncentrationerne af pitavastatin kan øges ved samtidig administration af EVOTAZ. 
Plasma concentrations of pitavastatin may be increased if co-administered with EVOTAZ.
Interaktionsmekanismen er atazanavirs og/eller cobicistats og clarithromycins 
The mechanism of interaction is CYP3A4 inhibition by atazanavir and/or cobicistat and clarithromycin.
Rifampicin 600 mg 1 gang dagligt (atazanavir 300 mg 1 gang dagligt med ritonavir 100 mg 1 gang dagligt) 
Rifampicin 600 mg once daily (atazanavir 300 mg once daily with ritonavir 100 mg once daily)
Plasmakoncentrationerne af rosuvastatin øges ved samtidig administration med atazanavir/cobicistat. 
Plasma concentrations of rosuvastatin are increased when coadministered with atazanavir/cobicistat.
Nevirapin 200 mg to gange dagligt (atazanavir 300 mg 1 gang dagligt med ritonavir 100 mg 1 gang dagligt) 
Nevirapine 200 mg twice daily (atazanavir 300 mg once daily with ritonavir 100 mg once daily)
Der er set unormal hjerterytme (puls) hos patienter, som anvender lægemidler med atazanavir. 
There have been reports of unusual heart beat in patients taking atazanavir-containing regimen.
Interaktionsmekanismen er bosentans CYP3A4-induktion. 
The mechanism of interaction is induction of CYP3A4 by bosentan.
Tenofoviralafenamid 10 mg 1 gang dagligt (atazanavir 300 mg 1 gang dagligt og cobicistat 150 mg 1 gang dagligt) 
Tenofovir alafenamide 10 mg once daily (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Osteonekrose 
ANTIGOUT Colchicine
Koncentrationerne for elbasvir steg betydeligt ved samtidig administration med atazanavir/ritonavir. 
Elbasvir concentrations were increased when co-administered with atazanavir/ritonavir
Interaktionsmekanismen er atazanavirs og cobicistats CYP3A-hæmning. 
The mechanism of interaction is CYP3A inhibition by atazanavir and cobicistat.
Nevirapin Cmax ↑17% (↑9% ↑25%) Nevirapin Cmin ↑32% (↑22% ↑43%) 
Nevirapine Cmin ↑32% (↑22%
Interaktionsmekanismen er cobicistats CYP3A4-hæmning. 
The mechanism of interaction is inhibition of CYP3A4 by cobicistat.
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. 
Do not double the next dose.
Gennemsnitlig halveringstid var, inden for atazanavirs dosisinterval, hos hiv-inficerede voksne patienter (n=33, kombinerede studier) 12 timer ved steady-state efter en dosis på 300 mg dagligt med 100 mg ritonavir én gang dagligt med et let måltid. 
12 hours at steady state following a dose of 300 mg daily with ritonavir 100 mg once daily with a light meal.
Nedsat nyrefunktion Atazanavir 
Renal impairment Atazanavir
Trazodons plasmakoncentrationer kan øges ved samtidig administration af EVOTAZ. 
Plasma concentrations of trazodone may be increased when co-administered with EVOTAZ.
Virkning og anvendelse 2. 
What EVOTAZ is and what it is used for 2.
Hvis du har glemt at tage en dosis inden for 12 timer efter det tidspunkt, du normalt tager EVOTAZ, skal du tage tabletten med mad så hurtigt som muligt. 
If you miss a dose of EVOTAZ by 12 hours or less, take it right away with food and then take your next scheduled dose at the usual time.
Koncentrationen af betablokkere kan øges ved samtidig administration af EVOTAZ. 
Concentrations of beta-blockers may be increased when co-administered with EVOTAZ.
Autoimmune lidelser (såsom Graves sygdom og autoimmun hepatitis) er også rapporteret i forbindelse med immunreaktivering. 
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.
Interaktionsmekanismen er atazanavirs og cobicistats CYP3A4-hæmning. 
The mechanism of interaction is inhibition of CYP3A4 by atazanavir and cobicistat.
EVOTAZ frarådes til patienter i hæmodialyse (se pkt. 
EVOTAZ is not recommended for patients undergoing haemodialysis (see sections 4.4 and 5.2).
4.4 og 4.5 for samtidig adminstration ved behandling af erektil dysfunktion), avanafil (PDE5-hæmmere) simvastatin og lovastatin (HMG-CoA reduktasehæmmere) (se pkt. 
Co-administration with the following medicinal products due to the potential for serious and/or lifethreatening adverse reactions (see section 4.5): colchicine, when used in patients with renal and/or hepatic impairment (antigout) (see section 4.5) sildenafil - when used for the treatment of pulmonary arterial hypertension (see sections 4.4 and 4.5 for co-administration for the treatment of erectile dysfunction), avanafil (PDE5 inhibitors) simvastatin and lovastatin (HMG-CoA reductase inhibitors) (see section 4.5) grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination (used to treat chronic hepatitis C infection) (see section 4.5) glecaprevir/pibrentasvir fixed dose combination (see section 4.5)
Integrasehæmmere 
Integrase Inhibitors
Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide. 
If you have any further questions, ask your doctor or pharmacist.
"Essentiel" betyder, at sygdommen ikke har nogen åbenlys årsag. 
‘Essential' means that the disease has no obvious cause.
Resultater ses sædvanligvis inden for to til tre uger efter påbegyndt behandling. 
Results are normally seen within 2 or 3 weeks of starting treatment.
Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Anagrelide Mylan. 
This is a summary of the European public assessment report (EPAR) for Anagrelide Mylan.
Den fuldstændige EPAR for Anagrelide Mylan findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
The full EPAR for Anagrelide Mylan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Efter en uge øges dosis hver uge med 0,5 mg dagligt, indtil blodpladetallet er under 600 mio. blodplader pr. ml og ideelt mellem 150 og 400 mio./ml (det antal, der normalt observeres hos sunde personer). 
After a week, the dose is increased every week by 0.5 mg a day, until the platelet count is below 600 million platelets per millilitre, and ideally between 150 and 400 million/ml (the level usually seen in healthy people).
Behandling bør kun iværksættes af en læge med erfaring i behandling af essentiel trombocytæmi. 
Treatment should only be started by a doctor who has experience in treating essential thrombocythaemia.
Agenturet anbefalede, at Anagrelide Mylan godkendes til anvendelse i EU. 
The Agency recommended that Anagrelide Mylan be approved for use in the EU.
Som for alle lægemidler fremlagde virksomheden undersøgelser af kvaliteten af Anagrelide Mylan. 
As for every medicine, the company provided studies on the quality of Anagrelide Mylan.
Anagrelide Mylan anvendes, når patientens hidtidige behandling ikke virker godt nok eller medfører uacceptable bivirkninger, og når patienten tilhører "risikogruppen" enten på grund af alder (over 60 år), meget højt blodpladetal eller tidligere størkningsproblemer. 
Anagrelide Mylan is used when the patient's current treatment does not work well enough or has unacceptable side effects, and when they are ‘at risk' because of their age (over 60 years), very high platelet counts or previous clotting problems.
Det betyder, at Anagrelide Mylan indeholder det samme aktive stof og virker på samme måde som et "referencelægemiddel", som allerede er godkendt i Den Europæiske Union (EU), og som hedder Xagrid. 
This means that Anagrelide Mylan contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Xagrid.
Anagrelide Mylan fås som kapsler (0,5 og 1 mg). 
Anagrelide Mylan is available as capsules (0.5 and 1 mg).
Det Europæiske Lægemiddelagentur konkluderede, at det i overensstemmelse med EU's krav er påvist, at Anagrelide Mylan er af sammenlignelig kvalitet og er bioækvivalent med Xagrid. 
The European Medicines Agency concluded that, in accordance with EU requirements, Anagrelide Mylan has been shown to have comparable quality and to be bioequivalent to Xagrid.
Den anbefalede startdosis er én 0,5-mg-kapsel to gange dagligt. 
The recommended starting dose is one 0.5 mg capsule twice a day.
Anagrelide Mylan er også et "hybridt lægemiddel", idet det fås i en yderligere styrke. 
Anagrelide Mylan is also a ‘hybrid medicine' because it is available in an additional strength.
Dette nedsætter blodpladetallet, hvorved symptomerne mindskes hos patienter med sygdommen. 
This reduces the platelet count, helping to improve symptoms in patients with the disease.
Den maksimale, anbefalede dosis Anagrelide Mylan er 2,5 mg ad gangen. 
The maximum recommended dose of Anagrelide Mylan is 2.5 mg at a time.
Der er allerede gennemført undersøgelser af fordelene og risiciene ved det aktive stof i den godkendte anvendelse med referencelægemidlet, Xagrid, og det er ikke nødvendigt at gentage disse for Anagrelide Mylan. 
Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Xagrid, and do not need to be repeated for Anagrelide Mylan.
Hvilke fordele og risici er der forbundet med Anagrelide Mylan? 
What are the benefits and risks of Anagrelide Mylan?
Hvad er Anagrelide Mylan, og hvad anvendes det til? 
What is Anagrelide Mylan and what is it used for?
Anagrelide Mylan er et lægemiddel, der anvendes til at mindske antallet af blodplader (bestanddele, der hjælper blodet til at størkne) hos patienter med essentiel trombocytæmi (en sygdom, hvor der er for mange blodplader i blodet). 
Anagrelide Mylan is a medicine used to reduce the number of platelets (components that help the blood to clot) in patients with essential thrombocythaemia (a disease in which there are too many platelets circulating in the blood).
Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Anagrelide Mylan? 
What measures are being taken to ensure the safe and effective use of Anagrelide Mylan?
Dette medfører øget risiko for blodpropper eller blødningsproblemer. 
This puts the patient at risk of developing blood clots or bleeding problems.
Anagrelide Mylan udleveres kun efter recept. 
Anagrelide Mylan can only be obtained with a prescription.
Andre oplysninger om Anagrelide Mylan 
Other information about Anagrelide Mylan
Hvis du ønsker yderligere oplysninger om behandling med Anagrelide Mylan, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek. 
For more information about treatment with Anagrelide Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Da Anagrelide Mylan er et generisk lægemiddel, som er bioækvivalent med referencelægemidlet, anses benefit/risk-forholdet for at være det samme som for referencelægemidlet. 
Because Anagrelide Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Det aktive stof i Anagrelide Mylan, anagrelid, blokerer udviklingen og væksten af celler i knoglemarven kaldet "megakaryocytter", som producerer blodplader. 
The active substance in Anagrelide Mylan, anagrelide, blocks the development and growth of cells in the bone marrow called ‘megakaryocytes', which produce platelets.
Det er ikke en praktisk vejledning i, hvordan Anagrelide Mylan bør anvendes. 
It is not intended to provide practical advice on how to use Anagrelide Mylan.
Det var derfor agenturets opfattelse, at fordelene opvejer de identificerede risici som for Xagrid. 
Therefore, the Agency's view was that, as for Xagrid, the benefit outweighs the identified risk.
Essentiel trombocytæmi er en sygdom, hvor knoglemarven producerer for mange blodplader. 
Essential thrombocythaemia is a disease in which the bone marrow produces too many platelets.
Hvorfor blev Anagrelide Mylan godkendt? 
Why is Anagrelide Mylan approved?
Anagrelide Mylan anagrelid 
Anagrelide Mylan anagrelide
Hvis du ønsker praktisk vejledning om anvendelsen af Anagrelide Mylan, kan du læse indlægssedlen eller kontakte din læge eller dit apotek. 
For practical information about using Anagrelide Mylan, patients should read the package leaflet or contact their doctor or pharmacist.
Der er anført anbefalinger og forholdsregler i produktresuméet og indlægssedlen, som patienter og sundhedspersonale skal følge for at sikre risikofri og effektiv anvendelse af Anagrelide Mylan. 
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Anagrelide Mylan have been included in the summary of product characteristics and the package leaflet.
Hvordan anvendes Anagrelide Mylan? 
How is Anagrelide Mylan used?
Hvordan blev Anagrelide Mylan undersøgt? 
How has Anagrelide Mylan been studied?
Anagrelide Mylan indeholder det aktive stof anagrelid. 
Anagrelide Mylan contains the active substance anagrelide and is a ‘generic medicine'.
Hvordan virker Anagrelide Mylan? 
How does Anagrelide Mylan work?
Bilag I Liste over særnavne, lægemiddelformer, lægemidlernes styrker, administrationsveje, indehavere af markedsføringstilladelse i medlemsstaterne 
Annex I List of the invented names, pharmaceutical forms, strengths of the medicinal products, route of administration, marketing authorisation holders in the member states
Storbritannien Genus Pharmaceuticals Holdings Limited, Park View House, 65 
United Kingdom Genus Pharmaceuticals Holdings Limited, Park View House, 65
Storbritannien Chelonia Healthcare Limited, Boumpoulinas 11, 3rd Floor, Nicosia, CY-1060 
United Kingdom Chelonia Healthcare Limited, Boumpoulinas 11, 3rd Floor, Nicosia, CY-1060
2 g meprobamat (i kombination med magnesiumoxid, magnesiumsufat, kaolin, sterculiagummi) 
2 g of meprobamate (in combination with magnesium oxide, magnesium sulphate, kaolin, sterculia gum)
400 mg meprobamat (i kombination med aceprometazin) 
400 mg of meprobamate (in combination with aceprometazine)
200 mg meprobamat (i kombination med medroxyprogesteronacetat og bendroflumethiazid) 
200 mg of meprobamate (in combination with medroxyprogesterone acetate bendroflumethiazide)
150 mg meprobamat (i kombination med kinin) 
150 mg of meprobamate (in combination with quinine)
Klinisk/sikkerhed 
Clinical/safety
Betingelser for markedsføringstilladelserne 
Conditions to the marketing authorisations
31. marts 2015: pilotundersøgelse 31. december hovedkohorte (resultater efter 1 år) 
2015:pilot study 31 December 2016: main cohort (1 year results)
Senest 30 dage efter 
Within 30 days after Commission Decision
Udsendelse af DHPC-meddelelse ifølge den handlingsplan og de betingelser, som CHMP har vedtaget. 
DHPC Communication circulation according to the CHMP agreed action plan and conditions.
Indehaveren af markedsføringstilladelsen skal udføre et PASS-undersøgelse med henblik på at håndtere alle vigtige, potentielle og identificerede risici, især parkinsonisme. 
The MAH will perform a PASS study to address all important, potential and identified risks, particularly Parkinsonism.
Den komplette undersøgelsesprotokol for den indlejrede case-kontrolundersøgelse inden for kohorten af »European Society of Cardiology« til undersøgelse af den potentielle forbindelse mellem ekstrapyramidale symptomer (EPS) og trimetazidin skal indsendes til medlemslandene/referencelandene senest 60 dage efter Kommissionens afgørelse og færdiggøres, inden undersøgelsen påbegyndes. 
The full study protocol for the nested case-control study within the European Society of Cardiology cohort, to investigate the potential association between extrapyramidal symptoms (EPS) and trimetazidine will be submitted to the MSs/RMS within 60 days after Commission Decision to be finalised prior to starting the study.
Indehaveren af markedsføringstilladelsen skal udføre en undersøgelse af lægemiddelanvendelse med henblik på at bekræfte receptudstederes overholdelse af den indskrænkede indikation efter ændringerne til markedsføringstilladelsen. 
The MAH should perform a drug utilization study to verify the compliance of prescribers regarding the restricted indication after marketing authorisation changes.
Den endelige undersøgelsesprotokol skal indsendes senest 60 dage efter Kommissionens afgørelse til medlemslandene/referencelandene med endelig vedtagelse, inden undersøgelsen påbegyndes. 
The final study protocol will be submitted within 60 days from Commission decision to MSs/RMS to be finally agreed prior to starting the study.
De nationale kompetente myndigheder i medlemslandet/medlemslandene eller referencelandet/referencelandene skal i givet fald sikre, at følgende betingelser opfyldes af indehaveren/indehaverne af markedsføringstilladelsen: 
National Competent Authorities (NCAs) of Member State(s) or Reference Member State(s) (RMS) where applicable, shall ensure that the following conditions are fulfilled by the MAH(s):
Indehaveren af markedsføringstilladelsen skal udføre en farmakokinetisk undersøgelse for at vurdere indvirkningen af nyreinsufficiens og alder på trimetazidin farmakokinetik ifølge den protokol, som CHMP har vedtaget. 
The MAH should perform a PK study assessing the effect of renal impairment and age on trimetazidine pharmacokinetics according to the CHMP agreed protocol.
Den endelige undersøgelsesrapport indsendes til medlemslandene/referencelandene den: 
The final study report will be submitted to MSs/RMS by:
Den endelige undersøgelsesrapport indsendes til de nationale kompetente myndigheder i medlemslandene eller referencelandene den: 
The final study report will be submitted to NCAs/RMS by:
De endelige resultater af undersøgelsen indsendes til de nationale kompetente myndigheder i medlemslandene eller referencelandene den: 
The final study results will be submitted to NCAs/RMS by:
Studiet skal gennemføres i henhold til en aftalt protokol. 
The study should be conducted according to an agreed protocol.
Dato for første markedsføringstilladelse: 25. juli 2019 
Date of first authorisation: 25 July 2019
Elektrokardiografi var heller ikke berørt. 
Electrocardiography was also unaffected.
Voksne (herunder ældre patienter) 
Adults (including the elderly)
En risiko for nyfødte/spædbørn kan dog ikke udelukkes. 
However, a risk to the newborns/infants cannot be excluded.
Der er ingen modgift. 
There is no antidote.
Brug til børn og unge (5-17 år) 
Use in children and adolescents (5 to 17 years)
Tag det ikke sammen med andre drikkevarer eller mad, eftersom dette kan nedsætte lægemidlets virkning. 
Do not take it with other drinks or food because they may reduce the medicine's effect.
Tag kun dette lægemiddel sammen med vand. 
Take this medicine with water only.
Overvågningen skal foregå mindst to gange om året. 
Frequency of monitoring is recommended to be at least twice a year.
Brug af Cufence sammen med mad og drikke 
Cufence with food and drink
Kapslerne skal sluges hele med vand. 
Capsules should be swallowed whole with water.
Derfor skal manifestationer på overbehandling overvåges. 
Therefore, monitoring for manifestations of overtreatment should be undertaken.
Stop ikke behandlingen uden at tale med lægen om det, heller ikke selvom du får det bedre. 
Do not stop or change your treatment without speaking with your doctor even if you feel better.
Der var derudover nogen tvivl om forholdet til trientin, eftersom lungefundene også blev observeret hos de fleste kontrolhunde i studiet på 26 uger. 
Moreover, there was some doubt about the relationship to trientine, as the lung findings were also observed in most of the control dogs in the 26 week study.
Neurologisk forværring kan forekomme i starten af behandlingen. 
Neurological deterioration can occur at the start of the treatment.
Andre produkter 
Other products
Eksponering lader til at variere betydeligt mellem forsøgspersoner. 
Exposure seems to be highly variable between subjects.
Denne effekt kan være mere fremtrædende hos patienter med eksisterende neurologiske symptomer. 
It is possible that this effect may be more evident in patients with pre-existing neurological symptoms.
Må ikke anvendes efter udløbsdatoen angivet på flaskens etiket og ydre karton. 
Do not use after the expiry date which is stated on the bottle label and outer carton.
Patienter, som har svært ved at synke, skal kontakte deres læge. 
Patients who have difficulties swallowing should contact their doctor.
Hvis du har glemt at tage en dosis, skal du tage din næste dosis til den planlagte tid. 
If you forget to take a dose take your next dose at its usual scheduled time.
Ikke kendt: Lupus nephritis 
Not known: Lupus nephritis
Endelig rapport: 4. kvartal 2025 (hovedstudie) 
Final report: Q4 2025 (main study)